IMR Press / FBL / Volume 8 / Issue 1 / DOI: 10.2741/986

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Replication of respiratory syncytial virus is inhibited in target cells generating nitric oxide in situ

Show Less
1 Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
2 Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, Maryland 20892
Front. Biosci. (Landmark Ed) 2003, 8(1), 48–53;
Published: 1 January 2003

Nitric oxide (NO) is generated by recruited inflammatory cells and by pulmonary epithelial cells in response to respiratory virus infection, although the relative antiviral efficacy of NO from each of these sources had not been clarified. To compare the direct, antiviral potency of NO from an exogenous source with that generated by target epithelial cells in situ, we transduced HEp-2 epithelial cells with the retroviral construct, pMFGS-NOS and cloned transductant lines that generated NO constitutively. We found that NO-producing HEp-2 cells could be infected with RSV, but the titer correlated inversely with NO production, an effect that was reversed by the NOS inhibitor, NG-methyl-L-arginine (NGMMA). Our results demonstrate that NO has significant direct antiviral activity against RSV, and interestingly, that the inhibitory effect is more potent in the presence of continuous, endogenous NO production than in response to NO from an exogenous source.

Back to top